TY - JOUR
T1 - Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma
AU - Pingali, Sai Ravi
AU - Saliba, Rima M.
AU - Anderlini, Paolo
AU - Hosing, Chitra
AU - Khouri, Issa
AU - Alousi, Amin M.
AU - Nieto, Yago
AU - Qazilbash, Muzaffar H.
AU - Champlin, Richard
AU - Popat, Uday R.
PY - 2017/7
Y1 - 2017/7
N2 - The impact of age at diagnosis on outcomes of patients with Hodgkin lymphoma (HL) undergoing autologous hematopoietic transplantation (auto-HCT) is unclear. We retrospectively evaluated the impact of age on outcomes of 310 consecutive patients with relapsed/refractory HL who underwent auto-HCT between January 1996 and December 2010 with carmustine, etoposide, cytarabine, and melphalan conditioning therapy. Patients were stratified into ≤ 55 and >55-year-age groups based on age at diagnosis. At a median follow-up of 80 (range, 1 to 180) months, progression-free survival was similar between both age groups. However, age older than 55 years at diagnosis was associated with significantly poor overall survival with a hazard ratio [HR] of 2.3 (P =.003) from higher rate of second malignancies (HR, 3.8; P =.015) compared with patients 55 years or younger. In conclusion age > 55 years at diagnosis increases risk of second malignancies after auto-HCT.
AB - The impact of age at diagnosis on outcomes of patients with Hodgkin lymphoma (HL) undergoing autologous hematopoietic transplantation (auto-HCT) is unclear. We retrospectively evaluated the impact of age on outcomes of 310 consecutive patients with relapsed/refractory HL who underwent auto-HCT between January 1996 and December 2010 with carmustine, etoposide, cytarabine, and melphalan conditioning therapy. Patients were stratified into ≤ 55 and >55-year-age groups based on age at diagnosis. At a median follow-up of 80 (range, 1 to 180) months, progression-free survival was similar between both age groups. However, age older than 55 years at diagnosis was associated with significantly poor overall survival with a hazard ratio [HR] of 2.3 (P =.003) from higher rate of second malignancies (HR, 3.8; P =.015) compared with patients 55 years or younger. In conclusion age > 55 years at diagnosis increases risk of second malignancies after auto-HCT.
KW - Age
KW - Autologous transplantation
KW - Hodgkin lymphoma
KW - Second malignancies
UR - http://www.scopus.com/inward/record.url?scp=85018260824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018260824&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.03.030
DO - 10.1016/j.bbmt.2017.03.030
M3 - Article
C2 - 28389254
AN - SCOPUS:85018260824
VL - 23
SP - 1059
EP - 1063
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 7
ER -